case_images: PMC8255476_01
case_images: PMC8255476_02
case_images: Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
case_images: fpsyt-12-669446-g0001.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0001.jpg
case_images: F1
case_images: At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
case_images: PMC8255476_03
case_images: Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
case_images: fpsyt-12-669446-g0001.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0001.jpg
case_images: F1
case_images: At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
case_images: Algorithm.
case_images: fpsyt-12-669446-g0002.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0002.jpg
case_images: F2
case_images: An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).
case_images: PMC8255476_04
case_images: PMC8255476_05
case_images: Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
case_images: fpsyt-12-669446-g0001.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0001.jpg
case_images: F1
case_images: At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
case_images: Algorithm.
case_images: fpsyt-12-669446-g0002.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0002.jpg
case_images: F2
case_images: An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).
case_images: PMC8255476_06
case_images: Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
case_images: fpsyt-12-669446-g0001.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0001.jpg
case_images: F1
case_images: At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
case_images: Algorithm.
case_images: fpsyt-12-669446-g0002.jpg
case_images: PMC8255476_06_fpsyt-12-669446-g0002.jpg
case_images: F2
case_images: An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).